Ocugen Announces Warrant Restructuring
Ocugen, Inc. (OCGN)
Company Research
Source: GlobeNewswire
MALVERN, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ: OCGN), a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases, today announced that it has entered into an amendment (the “Amendment”) to each of the warrants issued pursuant to the Securities Purchase Agreement dated June 13, 2019 with certain Investors to restructure each of the warrants held by each such investor. The effect of the Amendment is primarily that the Series C warrant holders have agreed to cancel the right to receive 30 million warrant shares for no consideration. Shankar Musunuri, Ph.D., MBA, Chairman, CEO and Co-Founder commented: "We believe that this warrant restructuring significantly benefits our current stockholders and further addresses the dilution that would have resulted from the previous agreement. We believe our shares are significantly undervalued and this dec
Show less
Read more
Impact Snapshot
Event Time:
OCGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCGN alerts
High impacting Ocugen, Inc. news events
Weekly update
A roundup of the hottest topics
OCGN
News
- IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the FirmPR Newswire
- INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of OcugenGlobeNewswire
- OCGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ocugen, Inc. Investors Can Join the Class Action Lawsuit!Accesswire
- Ocugen, Inc. (NASDAQ: OCGN) had its price target raised by analysts at Chardan Capital from $4.00 to $5.00. They now have a "buy" rating on the stock.MarketBeat
- DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the FirmAccesswire
OCGN
Earnings
- 11/9/23 - Beat
OCGN
Sec Filings
- 4/18/24 - Form S-3
- 4/18/24 - Form S-8
- 4/17/24 - Form 4
- OCGN's page on the SEC website